Cordis has obtained CE Mark approval in Europe for its Renlane renal denervation system, indicated for use in adult patients (> 18 years) with drug resistant hypertension to denervate the renal arteries to reduce blood pressure.
Cordis has completed the first successful cases with the Renlane renal denervation system at the University of Cologne Hospital in Germany.
The treated patients were diagnosed with resistant hypertension and had systolic blood pressures greater than or equal to 160mm Hg, despite undergoing traditional drug therapy with three or more anti-hypertensive medications.
The Renlane system, which used in conjunction with the Renlane multi-channel radiofrequency (RF) generator for energy delivery, includes an ablation catheter with a multi-channel RF ablation system. It has five irrigated electrodes located at the tip of the helical shaped, irrigated, ablation catheter.
Cordis worldwide president Celine Martin noted chronic hypertension poses a significant health risk to patients and also places a huge burden on global health care systems.
"We are pleased to make our Renlane renal denervation system available to European clinicians in need of solutions for patients who do not respond to traditional drug therapy. And we are looking forward to gaining more experience with this therapy and making it available to more patients in need of treatment around the world," Martin added.
According to Cordis, the Renlane renal denervation system is another addition to the company’s broad and growing portfolio of minimally invasive therapies for patients suffering from cardiovascular disease.